Literature DB >> 6214989

Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.

S Srinivasan, K P Fu, H C Neu.   

Abstract

The pharmacokinetics of moxalactam, a new beta-lactam antibiotic with an unusually broad spectrum of activity, were studied in normal volunteers and compared with the pharmacokinetics of cefazolin. After a 1,000-mg intramuscular injection of moxalactam, a mean peak serum level of 49 +/- 10 micrograms/ml was achieved at 30 to 60 min which was equivalent to the level achieved with 0.5 g of cefazolin. Serum levels of 4.57 +/- 0.63 micrograms/ml, above the inhibitory levels for most organisms, were present at 8 h. The half-life of moxalactam was 2.3 h. After a 30-min intravenous infusion of 1 g, the serum level of moxalactam was 60 +/- 18.8 micrograms/ml. This compares with a serum level of 70 micrograms/ml obtained with an infusion of 0.5 g of cefazolin. At 6 h, 3.59 +/- 0.68 microgram/ml of moxalactam was present. The half-life of moxalactam was 2.3 h, similar to that of cefazolin. By 1 h after administration, serum levels of moxalactam were higher after intramuscular administration than after intravenous delivery. Urinary recovery of the drug was 76% after intramuscular injection and 74% after intravenous infusion, with the majority of the drug having been excreted in the first 4 h after administration. Urinary recovery of cefazolin was 85%. The pharmacokinetics of moxalactam are similar to those of cefazolin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6214989      PMCID: PMC181414          DOI: 10.1128/AAC.19.2.302

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

Review 1.  Pharmacokinetics of cephalosporin antibiotics.

Authors:  J M Brogard; F Comte; M Pinget
Journal:  Antibiot Chemother (1971)       Date:  1978

2.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

3.  Pharmacokinetics of cefotaxime.

Authors:  K P Fu; P Aswapokee; I Ho; C Matthijssen; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

4.  Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins.

Authors:  J J Schrogie; J D Rogers; K C Yeh; R O Davies; G I Holmes; H Skeggs; C M Martin
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb

5.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

  5 in total
  17 in total

1.  Effect of probenecid on the pharmacokinetics of moxalactam.

Authors:  K A DeSante; K S Israel; G L Brier; J D Wolny; B L Hatcher
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

2.  Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

Authors:  K S Israel; H R Black; G L Brier; J D Wolny; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

3.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

4.  Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.

Authors:  S Srinivasan; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

5.  Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.

Authors:  M Ohkawa; S Hirano; S Tokunaga; I Motoi; R Shoda; A Ikeda; T Sugata; M Sawaki; M Shimamura; A Okasho; K Kuroda
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  The use of moxalactam in the treatment of serious infections due to multi-resistant organisms.

Authors:  S Srinivasan; E L Francke; C Ortiz-Neu; A S Prince; H C Neu
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

8.  Comparative pharmacokinetics of ceftazidime and moxalactam.

Authors:  T B Tjandramaga; A Van Hecken; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

9.  Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration.

Authors:  D B Lakings; E Novak; J M Friis; C M Lunan; L M Paxton
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.